Tumor infiltrating lymphocytes and PD-L1 expression in pre- and post-treatment breast cancers in the SWOG S0800 Phase II neoadjuvant chemotherapy trial

Our aim was to examine the association of pre-treatment tumor infiltrating lymphocyte (TIL) count and PD-L1 levels with pathologic complete response (pCR) and assess immune marker changes following treatment in tumor specimens from the S0800 clinical trial which randomized patients to bevacizumab+na...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Mol Cancer Ther
Päätekijät: Pelekanou, Vasiliki, Barlow, William E., Nahleh, Zeina A., Wasserman, Brad, Lo, Ying-Chun, von Wahlde, Marie-Kristin, Hayes, Daniel, Hortobagyi, Gabriel N., Gralow, Julie, Tripathy, Debu, Porter, Peggy, Szekely, Borbala, Hatzis, Christos, Rimm, David L., Pusztai, Lajos
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2018
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6548451/
https://ncbi.nlm.nih.gov/pubmed/29588392
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-17-1005
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia